Drug Chatter -- Tracking biopharma stock chatter

Profile for Cellectis S.A. (CLLS)

« Back to company index

CLLS Chatter Timeline

Stock Ticker for CLLS

Most Active Tweeters for CLLS

UserTweets
@portefeuillefun 40
@BehaviorFin 15
@datamonitor_JA 11
@JacobPlieth 8
@dispatchtribune 7

Recent Tweets for CLLS

PatrickPuerta @PatrickPuerta
RT @JacobPlieth: A Choulika says $CLLS previously halted UCART123 study is “resuming very soon” #Jefferies17
November 16th 2017, 11:11pm
intercooleronli @intercooleronli
Zacks Investment Research Lowers Cellectis S.A. $CLLS to Hold https://t.co/NTwLDObnbK
November 16th 2017, 8:11pm
ConsumerFeed @ConsumerFeed
Cellectis S.A. downgraded by Zacks Investment Research to hold. https://t.co/BqfRuQME5a $CLLS #CLLS
November 16th 2017, 8:11pm
RatingsNetwork @RatingsNetwork
Cellectis S.A. downgraded by Zacks Investment Research to hold. https://t.co/funT7zG9ED $CLLS #CLLS
November 16th 2017, 8:11pm
AmericanBanking @AmericanBanking
Cellectis S.A. downgraded by Zacks Investment Research to hold. https://t.co/TjJc7QuAl7 $CLLS #CLLS
November 16th 2017, 8:11pm
dispatchtribune @dispatchtribune
Cellectis S.A. $CLLS Downgraded to Hold at Zacks Investment Research https://t.co/AFqRS1sFMq
November 16th 2017, 8:11pm
AGCT_team @AGCT_team
RT @JacobPlieth: Kymriah & Yescarta cost $373-475k, so what would an allo $CLLS CAR cost? #Jefferies17 https://t.co/AhEaivWQPg
November 16th 2017, 11:11am
MikeFranks753 @MikeFranks753
RT @JacobPlieth: On cell therapy pricing, Choulika $CLLS says there's one thing "no one talks about": big pharma minimum floor is 85% gross…
November 16th 2017, 11:11am
PKnox26 @PKnox26
I highly recommend everyone check this out for finding good stocks to trade https://t.co/T16JbVBees $CLLS $CELG… https://t.co/31ntGh3Ylf
November 16th 2017, 10:11am
BehaviorFin @BehaviorFin
RT @JacobPlieth: $CLLS plan for UCARTCS1 #Jefferies17 https://t.co/4OBPHMESiO
November 16th 2017, 10:11am
okim59 @okim59
RT @JacobPlieth: What still needs to be done to improve on 1st approved CAR-T products? Choulika $CLLS : manufacturing pressure over time o…
November 16th 2017, 10:11am
BehaviorFin @BehaviorFin
RT @JacobPlieth: $CLLS currently in manufacturing campaign with UCART22. Aims to file US IND in H1 2018 #Jefferies17
November 16th 2017, 10:11am
BehaviorFin @BehaviorFin
RT @BiotechRadar: A.Choulika $CLLS $ALCLS Q: how is the AML patient going? A: not disclosing data, last we did stock fell (however they alr…
November 16th 2017, 10:11am
JacobPlieth @JacobPlieth
On cell therapy pricing, Choulika $CLLS says there's one thing "no one talks about": big pharma minimum floor is 85… https://t.co/GT2X4VFkQA
November 16th 2017, 7:11am
JacobPlieth @JacobPlieth
What still needs to be done to improve on 1st approved CAR-T products? Choulika $CLLS : manufacturing pressure over… https://t.co/0Lw0eiVh2h
November 16th 2017, 7:11am
MikeFranks753 @MikeFranks753
RT @BiotechRadar: A.Choulika $CLLS $ALCLS UCART products intended to be a ‘1st line products’, 50-60k cells actually active per dose (for U…
November 16th 2017, 6:11am
JacobPlieth @JacobPlieth
$CLLS plan for UCARTCS1 #Jefferies17 https://t.co/4OBPHMESiO
November 16th 2017, 6:11am
BiotechRadar @BiotechRadar
A.Choulika $CLLS $ALCLS Q: how is the AML patient going? A: not disclosing data, last we did stock fell (however th… https://t.co/EgqNohFrHy
November 16th 2017, 6:11am
JacobPlieth @JacobPlieth
$CLLS currently in manufacturing campaign with UCART22. Aims to file US IND in H1 2018 #Jefferies17
November 16th 2017, 6:11am
JacobPlieth @JacobPlieth
$CLLS says it’s still trying to figure out if it needs alemtuzumab. Might not - cells engraft fine without… https://t.co/e3CDkZWZrp
November 16th 2017, 6:11am
BiotechRadar @BiotechRadar
A.Choulika $CLLS $ALCLS UCART products intended to be a ‘1st line products’, 50-60k cells actually active per dose… https://t.co/YmZqtlrXB2
November 16th 2017, 5:11am
JacobPlieth @JacobPlieth
Kymriah & Yescarta cost $373-475k, so what would an allo $CLLS CAR cost? #Jefferies17 https://t.co/AhEaivWQPg
November 16th 2017, 5:11am
JacobPlieth @JacobPlieth
A Choulika says $CLLS previously halted UCART123 study is “resuming very soon” #Jefferies17
November 16th 2017, 5:11am
dailypoliticaln @dailypoliticaln
Cellectis S.A. $CLLS Short Interest Up 62.5% in October https://t.co/LpVeg8WtlH
November 16th 2017, 4:11am
dailymailtimes @dailymailtimes
Cellectis S.A. $CLLS Short Interest Up 62.5% in October https://t.co/EF5DDdltWd
November 16th 2017, 4:11am
WKRBNews @WKRBNews
Cellectis S.A. $CLLS Short Interest Up 62.5% in October https://t.co/9rQiylPmN3
November 16th 2017, 4:11am
midetimes @midetimes
Cellectis S.A. $CLLS Short Interest Up 62.5% in October https://t.co/7E1EVVaJay
November 16th 2017, 4:11am
AmericanBanking @AmericanBanking
Cellectis S.A. $CLLS Receives Consensus Recommendation of “Buy” from Analysts https://t.co/7z9xEew6pR
November 16th 2017, 4:11am
intercooleronli @intercooleronli
Cellectis S.A. $CLLS Receives Consensus Recommendation of “Buy” from Analysts https://t.co/SbSUpyzQ7j
November 16th 2017, 4:11am
ConsumerFeed @ConsumerFeed
Cellectis S.A. $CLLS Receives Consensus Recommendation of “Buy” from Analysts https://t.co/QUVH9nIHTx #acn
November 16th 2017, 4:11am
WatchlistN @WatchlistN
Cellectis S.A. $CLLS Receives Consensus Recommendation of “Buy” from Analysts https://t.co/5Gqu9W9tpq
November 16th 2017, 4:11am
CFinancialNews @CFinancialNews
Cellectis S.A. $CLLS Receives Consensus Recommendation of “Buy” from Analysts https://t.co/KP9vGw1KHe
November 16th 2017, 4:11am
portefeuillefun @portefeuillefun
$CLLS +4% in Paris trading. As usual, don’t come whining no one told you when to buy (and when to sell) :) $ALCLS
November 16th 2017, 3:11am
amitkjolly @amitkjolly
RT @tgtxdough: Laden $CLLS market confusion&unwarranted selloff to the otherwise strong ASH abstracts create a buying opportunity for $CLLS…
November 15th 2017, 2:11pm
BehaviorFin @BehaviorFin
RT @portefeuillefun: @stevedoc22 It could, but I don't see why it should and $CLLS has recently stressed that they can pretty much treat ev…
November 15th 2017, 1:11pm
RoccoLefkowitz @RoccoLefkowitz
Added 500 $CLLS at 23.5 for total 1000 shares cost basis 24.75. https://t.co/zSjA9odFGo
November 15th 2017, 1:11pm
BehaviorFin @BehaviorFin
RT @Gupta_Calling: $clls Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017 https://t.co/N2B0c29qar
November 15th 2017, 12:11pm
CaesarBiotech @CaesarBiotech
RT @Gupta_Calling: $clls JEFFRIES TP $47 https://t.co/TBBAweiGBe
November 15th 2017, 12:11pm
Gupta_Calling @Gupta_Calling
$clls JEFFRIES TP $47 https://t.co/TBBAweiGBe
November 15th 2017, 11:11am
Gupta_Calling @Gupta_Calling
$clls Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017 https://t.co/N2B0c29qar
November 15th 2017, 11:11am
Gupta_Calling @Gupta_Calling
$clls #ASH17 PRESENTATIONS https://t.co/3OkBbUPomD
November 15th 2017, 11:11am
FinanciallyInd @FinanciallyInd
$BOLD $CLLS https://t.co/ceE5bGAp58
November 15th 2017, 10:11am
portefeuillefun @portefeuillefun
@stevedoc22 It could, but I don't see why it should and $CLLS has recently stressed that they can pretty much treat… https://t.co/k2zn2JfdOT
November 15th 2017, 8:11am
portefeuillefun @portefeuillefun
@tgtxdough Ladenburg Thalmann estimate of the proper $CLLS valuation. $ALCLS https://t.co/wLdSG549DA
November 15th 2017, 7:11am
tgtxdough @tgtxdough
Laden $CLLS market confusion&unwarranted selloff to the otherwise strong ASH abstracts create a buying opportunity… https://t.co/A2VjWuQxas
November 15th 2017, 7:11am
ledgerzette @ledgerzette
Contrasting Incyte Corporation $INCY & Cellectis $CLLS https://t.co/0Mimz5ZwSE
November 15th 2017, 3:11am
SleekMoneycom @SleekMoneycom
Cellectis $CLLS Given Daily Media Impact Score of 0.21 https://t.co/hv5Lv93nUy
November 14th 2017, 10:11pm
PatrickPuerta @PatrickPuerta
RT @bradloncar: $CLLS André Choulika said on Q3 call that the cost of goods per vial of the company's allogeneic CAR-T is currently < $4,00…
November 14th 2017, 7:11pm
portefeuillefun @portefeuillefun
correction: Bought 1000 $CLLS at $23.48, now 16000 #vssporte shares.
November 14th 2017, 3:11pm
portefeuillefun @portefeuillefun
Bought 2000 $CLLS at $23.48, now 16000 #vssporte shares.
November 14th 2017, 3:11pm

Contact © thinkBiotech LLC 2004 - 2017. All rights reserved.